Brief: Matinas Biopharma Provides Update To Mat2203 Regulatory And Development Pathway after Feedback From FDA
21/12/2023 12:40
Dec 21 (Reuters) - Matinas BioPharma Holdings Inc
MTNB.A :
* MATINAS BIOPHARMA PROVIDES UPDATE TO MAT2203 REGULATORY
AND
DEVELOPMENT PATHWAY FOLLOWING FEEDBACK FROM FDA
* MATINAS-PLANNING MEETING EARLY IN Q1 2024 TO DISCUSS &
FINALIZE
PHASE 3 PROTOCOL & POSITION MAT2203 TO COMMENCE PHASE 3 AS SOON
AS POSSIBLE THEREAFTER
Source text for Eikon: ID:nGNX2TB640
Further company coverage: MTNB.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Matinas BioPharma Holdings
See all newsBrief: GH Power Signs Multi-Year Hydrogen Offtake Agreement With Change Energy For Hamilton Facility Output
Brief: Gh Power And Tkms Continue To Explore Clean Energy Collaboration In Support Of Canada’S Future Patrol Submarine Project
Brief: Matinas Biopharma - Btig Terminates Sales Agreement With Matinas Biopharma Holdings, Effective Immediately On July 23, 2026 - SEC Filing
Brief: Matinas Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards And Acceptance Of Plan To Regain Compliance
Brief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing